Tag: Bristol Myers Squibb
New Hope in Multiple Myeloma Treatment as FDA Approves Zenbexus-Based Regimen
The U.S. Food and Drug Administration has granted accelerated approval to Zenbexus(iberdomide), Bristol Myers Squibb's oral cereblon-modulating protein degrader, for use alongside daratumumab and hyaluronidase-fihj and dexamethasone in adults with...
Bristol Myers Squibb Secures Dual Regulatory Wins for Opdivo® in Classical Hodgkin Lymphoma
Bristol Myers Squibb (NYSE: BMY) announced that Opdivo® (nivolumab) has received approval for two new classical Hodgkin Lymphoma (cHL) indications in the U.S. and...
